ipss-r vs ipss-m for mds
Published 2 years ago • 569 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
2:23
benefits, applicability & uses of the ipss-m in mds
-
1:35
ipss-m: prognostic power in hma-treated mds patients
-
6:04
relevance of ipss-r for risk stratification in patients with mds who undergo sct
-
3:57
validation of the ipss-m risk stratification system in mds
-
1:45
evaluating ipss-r and ipss-m in patients with hr-mds enrolled in stimulus-mds1 and stimulus-mds2
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
3:35
real-world validation of the value of the ipss-m for prognostication in patients with mds
-
9:16
protrombin time (pt) & activated partial tromboplastin time (aptt)|coagulation analyzer|wila djami
-
7:11
treatment of older mds patients with bmt (bone marrow transplantation)
-
1:29:13
myelodysplastic syndrome
-
3:31
relevance of the ipss-r during sct in patients with mds in the molecular classification era
-
1:14
how the ipss-m score helps personalizing treatment & combination therapies in hr-mds
-
1:34
feasibility of the ipss-m in cmml
-
1:16
state of the art: mds
-
1:26
current and emerging prognostic factors for mds/mpn
-
3:08
the treatment protocol for higher risk mds
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
1:04
the future of mds management
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
1:41
an overview of the mds diagnosis pathway
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
2:21
precision medicine for mds, what drugs for which patients?